145 related articles for article (PubMed ID: 24706357)
1. Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma.
Riehmer V; Gietzelt J; Beyer U; Hentschel B; Westphal M; Schackert G; Sabel MC; Radlwimmer B; Pietsch T; Reifenberger G; Weller M; Weber RG; Loeffler M;
Genes Chromosomes Cancer; 2014 Jul; 53(7):589-605. PubMed ID: 24706357
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
Reifenberger G; Weber RG; Riehmer V; Kaulich K; Willscher E; Wirth H; Gietzelt J; Hentschel B; Westphal M; Simon M; Schackert G; Schramm J; Matschke J; Sabel MC; Gramatzki D; Felsberg J; Hartmann C; Steinbach JP; Schlegel U; Wick W; Radlwimmer B; Pietsch T; Tonn JC; von Deimling A; Binder H; Weller M; Loeffler M;
Int J Cancer; 2014 Oct; 135(8):1822-31. PubMed ID: 24615357
[TBL] [Abstract][Full Text] [Related]
3. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
Ho WM; Chen CY; Chiang TW; Chuang TJ
Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Kim J; Lee IH; Cho HJ; Park CK; Jung YS; Kim Y; Nam SH; Kim BS; Johnson MD; Kong DS; Seol HJ; Lee JI; Joo KM; Yoon Y; Park WY; Lee J; Park PJ; Nam DH
Cancer Cell; 2015 Sep; 28(3):318-28. PubMed ID: 26373279
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
8. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
Ramkissoon SH; Bi WL; Schumacher SE; Ramkissoon LA; Haidar S; Knoff D; Dubuc A; Brown L; Burns M; Cryan JB; Abedalthagafi M; Kang YJ; Schultz N; Reardon DA; Lee EQ; Rinne ML; Norden AD; Nayak L; Ruland S; Doherty LM; LaFrankie DC; Horvath M; Aizer AA; Russo A; Arvold ND; Claus EB; Al-Mefty O; Johnson MD; Golby AJ; Dunn IF; Chiocca EA; Trippa L; Santagata S; Folkerth RD; Kantoff P; Rollins BJ; Lindeman NI; Wen PY; Ligon AH; Beroukhim R; Alexander BM; Ligon KL
Neuro Oncol; 2015 Oct; 17(10):1344-55. PubMed ID: 25754088
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
10. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
11. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
12. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
13. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
[TBL] [Abstract][Full Text] [Related]
15. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
16. From astrocytoma to glioblastoma: a clonal evolution study.
Yang F; Zou Y; Gong Q; Chen J; Li WD; Huang Q
FEBS Open Bio; 2020 May; 10(5):744-751. PubMed ID: 32069381
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
18. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
[TBL] [Abstract][Full Text] [Related]
20. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
Mandel JJ; Cachia D; Liu D; Wilson C; Aldape K; Fuller G; de Groot JF
J Neurooncol; 2016 Aug; 129(1):147-54. PubMed ID: 27270908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
